Display Settings:


Send to:

Choose Destination
See comment in PubMed Commons below
J Korean Med Sci. 2013 Aug;28(8):1248-52. doi: 10.3346/jkms.2013.28.8.1248. Epub 2013 Jul 31.

Imatinib plasma monitoring-guided dose modification for managing imatinib-related toxicities in gastrointestinal stromal tumor patients.

Author information

  • 1Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.


Imatinib, the first-line treatment in patients with advanced gastrointestinal stromal tumors (GIST), is generally well tolerated, although some patients have difficulty tolerating the standard dose of 400 mg/day. Adjusting imatinib dosage by plasma level monitoring may facilitate management of patients who experience intolerable toxicities due to overexposure to the drug. We present two cases of advanced GIST patients in whom we managed imatinib-related toxicities through dose modifications guided by imatinib plasma level monitoring. Imatinib blood level testing may be a promising approach for fine-tuning imatinib dosage for better tolerability and optimal clinical outcomes in patients with advanced GIST.


Dose-Modification; Gastrointestinal Stromal Tumors (GIST); Imatinib; Imatinib Plasma Monitoring

[PubMed - indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Korean Academy of Medical Sciences Icon for PubMed Central
    Loading ...
    Write to the Help Desk